Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone.
Notwithstanding recent treatment advances in metastatic colorectal cancer (mCRC), chemotherapy with a combination of a fluoropyrimidine and a folate agent, often 5-fluorouracil (5-FU) and leucovorin, remains the backbone of treatment regimens for the majority of patients with mCRC. This is despite a recent focus on molecular-targeted treatments and patient stratification according to mutational status or expression levels of specific genes. Intracellular folate concentration was discovered to be pivotal in the cytotoxic efficacy of 5-FU, paving the way to the current standard combination therapy approach. Subsequent discovery that systemic chemotherapy agents, such as irinotecan and oxaliplatin, can further increase the efficacy of 5-FU-based treatments led to the development of several combination chemotherapy regimens, including FOLFOX, FOLFIRI and FOLFOXIRI. Subsequent efforts to optimise 5-FU-based treatments have focused on 5-FU analogues, initially capecitabine and the combination drug tegafur/gimeracil/oteracil (S-1) and then TAS-102, which has recently been evaluated in phase 3 clinical trials for refractory colorectal cancer. Further approaches taken to improve the efficacy of 5-FU chemotherapy regimens have focused on optimising the route and dosing schedules and regulating folate metabolism. Pharmacokinetic variability caused by the requirement for metabolic conversion of leucovorin has been central to recent research, and the development of agents such as arfolitixorin which bypass the need for metabolic conversion remains promising for future therapeutic candidates. In this review, we summarise the evidence leading to the current treatment regimens employing 5-FU and leucovorin, focusing on recent approaches taken to optimise and refine treatments to improve clinical outcomes in patients with mCRC.
['Glimelius|Bengt|B|', 'Stintzing|Sebastian|S|', 'Marshall|John|J|', 'Yoshino|Takayuki|T|', 'de Gramont|Aimery|A|']
D000818:Animals D000971:Antineoplastic Combined Chemotherapy Protocols D000069287:Capecitabine D015179:Colorectal Neoplasms D005472:Fluorouracil D005492:Folic Acid D006801:Humans D000077146:Irinotecan D002955:Leucovorin D000077150:Oxaliplatin D011379:Prognosis
Metastatic colorectal cancer Chemotherapy 5-fluorouracil Leucovorin